vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and WIDEPOINT CORP (WYY). Click either name above to swap in a different company.

WIDEPOINT CORP is the larger business by last-quarter revenue ($42.3M vs $37.2M, roughly 1.1× GYRE THERAPEUTICS, INC.). WIDEPOINT CORP runs the higher net margin — -2.0% vs -3.7%, a 1.7% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 12.3%). WIDEPOINT CORP produced more free cash flow last quarter ($-270.0K vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 11.2%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

WidePoint Corporation is an American company based in Fairfax, Virginia that provides technology-based products and services to the government sector and commercial markets in the United States. The company holds a patent for a digital parsing tool that allows users to access accounts through a secure repository gateway, established using asymmetric authentication employed as public key infrastructure (PKI). WidePoint provides smart card identity verification, wireless expense management, pen...

GYRE vs WYY — Head-to-Head

Bigger by revenue
WYY
WYY
1.1× larger
WYY
$42.3M
$37.2M
GYRE
Growing faster (revenue YoY)
GYRE
GYRE
+21.2% gap
GYRE
33.4%
12.3%
WYY
Higher net margin
WYY
WYY
1.7% more per $
WYY
-2.0%
-3.7%
GYRE
More free cash flow
WYY
WYY
$5.5M more FCF
WYY
$-270.0K
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
11.2%
WYY

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GYRE
GYRE
WYY
WYY
Revenue
$37.2M
$42.3M
Net Profit
$-1.4M
$-849.4K
Gross Margin
95.3%
13.8%
Operating Margin
0.3%
-1.9%
Net Margin
-3.7%
-2.0%
Revenue YoY
33.4%
12.3%
Net Profit YoY
-340.1%
-138.3%
EPS (diluted)
$-0.01
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
WYY
WYY
Q4 25
$37.2M
$42.3M
Q3 25
$30.6M
$36.1M
Q2 25
$26.8M
$37.9M
Q1 25
$22.1M
$34.2M
Q4 24
$27.9M
$37.7M
Q3 24
$25.5M
$34.6M
Q2 24
$25.2M
$36.0M
Q1 24
$27.2M
$34.2M
Net Profit
GYRE
GYRE
WYY
WYY
Q4 25
$-1.4M
$-849.4K
Q3 25
$5.9M
$-559.2K
Q2 25
$1.6M
$-618.5K
Q1 25
$3.7M
$-724.1K
Q4 24
$569.0K
$-356.4K
Q3 24
$2.9M
$-425.2K
Q2 24
$4.5M
$-499.6K
Q1 24
$9.9M
$-653.1K
Gross Margin
GYRE
GYRE
WYY
WYY
Q4 25
95.3%
13.8%
Q3 25
94.7%
14.6%
Q2 25
95.7%
13.5%
Q1 25
95.9%
14.0%
Q4 24
95.8%
12.6%
Q3 24
96.2%
13.6%
Q2 24
96.9%
13.6%
Q1 24
96.4%
13.6%
Operating Margin
GYRE
GYRE
WYY
WYY
Q4 25
0.3%
-1.9%
Q3 25
22.7%
-1.3%
Q2 25
8.1%
-1.9%
Q1 25
10.3%
-2.4%
Q4 24
2.4%
-0.8%
Q3 24
16.6%
-1.3%
Q2 24
12.7%
-1.3%
Q1 24
29.7%
-1.9%
Net Margin
GYRE
GYRE
WYY
WYY
Q4 25
-3.7%
-2.0%
Q3 25
19.4%
-1.5%
Q2 25
5.9%
-1.6%
Q1 25
16.9%
-2.1%
Q4 24
2.0%
-0.9%
Q3 24
11.2%
-1.2%
Q2 24
18.0%
-1.4%
Q1 24
36.6%
-1.9%
EPS (diluted)
GYRE
GYRE
WYY
WYY
Q4 25
$-0.01
$-0.08
Q3 25
$0.03
$-0.06
Q2 25
$0.00
$-0.06
Q1 25
$0.00
$-0.08
Q4 24
$0.00
$-0.05
Q3 24
$0.01
$-0.04
Q2 24
$0.01
$-0.05
Q1 24
$0.03
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
WYY
WYY
Cash + ST InvestmentsLiquidity on hand
$52.4M
$9.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$106.0M
$11.5M
Total Assets
$166.1M
$79.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
WYY
WYY
Q4 25
$52.4M
$9.8M
Q3 25
$60.0M
$12.1M
Q2 25
$54.4M
$6.8M
Q1 25
$29.9M
$3.7M
Q4 24
$26.7M
$6.8M
Q3 24
$25.1M
Q2 24
$25.1M
Q1 24
$37.4M
Stockholders' Equity
GYRE
GYRE
WYY
WYY
Q4 25
$106.0M
$11.5M
Q3 25
$101.9M
$12.2M
Q2 25
$92.0M
$12.6M
Q1 25
$68.1M
$13.0M
Q4 24
$63.3M
$13.6M
Q3 24
$63.2M
$13.8M
Q2 24
$60.4M
$14.0M
Q1 24
$56.6M
$14.2M
Total Assets
GYRE
GYRE
WYY
WYY
Q4 25
$166.1M
$79.8M
Q3 25
$159.4M
$70.6M
Q2 25
$152.6M
$76.6M
Q1 25
$129.8M
$71.4M
Q4 24
$125.4M
$71.6M
Q3 24
$125.2M
$56.9M
Q2 24
$120.9M
$58.6M
Q1 24
$122.0M
$54.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
WYY
WYY
Operating Cash FlowLast quarter
$-5.6M
$-173.5K
Free Cash FlowOCF − Capex
$-5.8M
$-270.0K
FCF MarginFCF / Revenue
-15.5%
-0.6%
Capex IntensityCapex / Revenue
0.4%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K
$5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
WYY
WYY
Q4 25
$-5.6M
$-173.5K
Q3 25
$4.7M
$5.9M
Q2 25
$2.1M
$3.2M
Q1 25
$-129.0K
$-3.2M
Q4 24
$-2.8M
$2.4M
Q3 24
$1.7M
$1.9M
Q2 24
$-5.5M
$-1.1M
Q1 24
$2.9M
$-1.6M
Free Cash Flow
GYRE
GYRE
WYY
WYY
Q4 25
$-5.8M
$-270.0K
Q3 25
$4.0M
$5.9M
Q2 25
$1.8M
$3.1M
Q1 25
$-251.0K
$-3.3M
Q4 24
$-2.8M
$2.4M
Q3 24
$1.0M
$1.8M
Q2 24
$-6.9M
$-1.1M
Q1 24
$2.7M
$-1.6M
FCF Margin
GYRE
GYRE
WYY
WYY
Q4 25
-15.5%
-0.6%
Q3 25
13.1%
16.4%
Q2 25
6.8%
8.1%
Q1 25
-1.1%
-9.5%
Q4 24
-10.1%
6.4%
Q3 24
4.1%
5.3%
Q2 24
-27.5%
-3.0%
Q1 24
9.8%
-4.6%
Capex Intensity
GYRE
GYRE
WYY
WYY
Q4 25
0.4%
0.2%
Q3 25
2.2%
0.1%
Q2 25
1.0%
0.2%
Q1 25
0.6%
0.1%
Q4 24
0.2%
0.1%
Q3 24
2.7%
0.2%
Q2 24
5.8%
0.0%
Q1 24
0.9%
0.0%
Cash Conversion
GYRE
GYRE
WYY
WYY
Q4 25
Q3 25
0.79×
Q2 25
1.32×
Q1 25
-0.03×
Q4 24
-4.85×
Q3 24
0.60×
Q2 24
-1.21×
Q1 24
0.29×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GYRE
GYRE

Segment breakdown not available.

WYY
WYY

Carrier Services$26.8M63%
Managed Services$15.5M37%

Related Comparisons